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Clear cell-type renal cell carcinomas (clear RCC) are characterized
almost universally by loss of heterozygosity on chromosome 3p,
which usually involves any combination of three regions: 3p25-p26
(harboring the VHL gene), 3p12-p14.2 (containing the FHIT gene),
and 3p21-p22, implying inactivation of the resident tumor-
suppressor genes (TSGs). For the 3p21-p22 region, the affected
TSGs remain, at present, unknown. Recently, the RAS association
family 1 gene (isoform RASSF1A), located at 3p21.3, has been
identified as a candidate lung and breast TSG. In this report, we
demonstrate aberrant silencing by hypermethylation of RASSF1A
in both VHL-caused clear RCC tumors and clear RCC without VHL
inactivation. We found hypermethylation of RASSF1A’s GC-rich
putative promoter region in most of analyzed samples, including
39 of 43 primary tumors (91%). The promoter was methylated
partially or completely in all 18 RCC cell lines analyzed. Methylation
of the GC-rich putative RASSF1A promoter region and loss of
transcription of the corresponding mRNA were related causally.
RASSF1A expression was reactivated after treatment with 5-aza-
2*-deoxycytidine. Forced expression of RASSF1A transcripts in
KRCyY, a renal carcinoma cell line containing a normal and ex-
pressed VHL gene, suppressed growth on plastic dishes and an-
chorage-independent colony formation in soft agar. Mutant
RASSF1A had reduced growth suppression activity significantly.
These data suggest that RASSF1A is the candidate renal TSG gene
for the 3p21.3 region.
Loss of heterozygosity (LOH) of chromosome 3p is the mostcommon event in clear cell-type renal cell carcinomas (clear
RCC). It involves one or more of the three major commonly
deleted regions (1–3) that may be subdivided further by using
pioneering stringent criteria for LOH analysis (4–6).
The most frequent form of hereditary RCC is the familial
VHL cancer syndrome (7). The VHL gene was mapped to 3p25
and was isolated by positional cloning (8). It was inactivated by
intragenic and genomic deletions and various kinds of mutations
in 100% of analyzed VHL families and in a large portion of
sporadic clear RCC (9). Inactivation of VHL by promoter
hypermethylation (10) in sporadic clear RCC was noted also and
was observed quite frequently (20%). However, in other spo-
radic clear RCC (reaching in some studies 30–50%) and some
non-VHL clear RCC families (11, 12), VHL was not affected (see
review in ref. 13).
Another commonly deleted region was found at 3p12-p14.
Although the overall frequency of the specific LOH is not high,
chromosome transfer experiments indicated that the 3p12-p14
region could suppress the tumorigenic properties of some clear
RCC cell lines (14), implying the presence of a gene or genes
involved in the origin andyor development of clear RCC. This
role may be attributed to the FHIT gene at 3p14.3 (15), andyor
other tumor-suppressor genes (TSGs) residing in 3p12.
Multiple studies have identified LOH on 3p21-p22 as the most
frequent 3p loss in renal tumor development (4, 5, 16, 17).
Recent data indicate that this region consists of two distinct
subregions: centromeric 3p21.3 and telomeric 3p21.3-p22, with
both regions being deleted frequently (5). The same broad
region (3p21-p22) was implicated in tumorigenesis of several
other histologically different malignancies, including homozy-
gous deletions at 3p21.3 in lung and breast tumors (4, 18).
Recently, a new RAS effector homolog gene, RASSF1, was
located within the critical lung and breast cancer deletion region
at centromeric 3p21.3 (18, 19). Two distinct GC-rich promoters
produced RASSF1A and RASSF1C transcripts. RASSF1A
mRNA was missing in most analyzed small-cell lung cancer cell
lines because of methylation of the RASSF1A putative promoter
region (19–21). Interestingly, the RASSF1A protein interacts
with the DNA repair protein, XPA (19). As seen with the mouse
Ras effector protein Nore1 and its rat ortholog Maxp1, the
human RASSF1A isoform (but not RASSF1C) has high homol-
ogy to the cysteine-rich diacylglycerolyphorbolester-binding do-
main, also known as the protein kinase C conserved region 1.
Reexpression of the RASSF1A transcript in lung carcinoma cells
reduced colony formation, suppressed anchorage-independent
growth, and inhibited tumor formation in nude mice (19, 20).
In this report, we addressed the possible role of this putative
lung and breast TSG in renal tumorigenesis. Our data suggest
that the RASSF1A gene is a candidate renal TSG for the
centromeric 3p21.3 region.
Materials and Methods
Cell Lines. The 786-0 and ACHN RCC cell lines were purchased
from ATCC. A498, CAKI 1, CAKI 2, HN4, HN51, KH39,
KRCyY, TK10, and TK164 were described in ref. 5. The L24 line
and L&U3-L&U6 somatic-cell hybrid clones were established as
reported (22).
Analysis of RASSF1A Promoter Methylation. Bisulfite DNA treat-
ment has been described (22). Amplification of bisulfite-
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converted RASSF1A promoter sequences was carried with an
upstream primer B-Ras-E-1D, GTA GGT TAA GTG TGT TGT
TTT AGT A, and a downstream primer B-Ras-E-4R, ACC
AAA AAC CAA CTA CCR TAT AAA ATT. Nested PCR was
conducted by using primers B-Ras-E-2D, AGT ATA GTA AAG
TTG GTT TTT AGA AAT A (upstream), and B-Ras-E-6R,
AAT ACC AAC TCC CRC AAC TCA ATA AAC TCA
(downstream). For amplification of RASSF1C bisulfite-treated
promoter sequences, we used primers BISLU7–1D, AGT GAT
GAG GTT ATT TTT GGG GG; BISLU7–1R, CTC TTA ACT
ACA ATA ACC ACT ACT C (first PCR); BISLU7–2D, TTG
TTT TAA TGA GAT AAG AGT TAG ATT; and BISLU7–2R,
TCA TAC TAC TCC AAA TCA TTT CAA AAA (nested
PCR). Each PCR amplification consisted of 35 cycles; 94°C for
30 sec, 58°C for 30 sec, and 72°C for 40 sec. For combined
bisulfite-restriction analysis (COBRA), PCR products were cut
with BstUI or MspI and separated on a 4–20% TBE (90 mM
Trisy64.6 mM boric acidy2.5 mM EDTA, pH 8.3) polyacryl-
amide gel (Invitrogen). The principles of the COBRA procedure
were described by Xiong and Laird (23).
For sequencing of PCR products obtained from bisulfite-
treated genomic DNA, the fragments were subcloned into the
pCR2.1 plasmid (TA cloning kit, Invitrogen) and several clones
for each cell line were sequenced by using a 373 stretch DNA
sequencer (Applied Biosystems).
Methylation-specific PCR was performed as described (20).
RASSF1A Expression Study. The 380-bp HindIIIySmaI fragment of
the RASSF1A cDNA insert that included exons 1a and 2ab (19)
was subcloned into pBluescript II SK(1) vector. A 20-bp dele-
tion was created within the cDNA insert by digestion of the
plasmid with XcaIyMscI and religation. The resulting plasmid
was cut with SmaI, and artificial run-off RNA was generated by
using the T7 MEGAscript kit (Ambion, Austin, TX). VHL group
7 cDNA was digested with BstEII and XbaI. A BstEIIyXbaI
fragment, containing exon 2 and part of exon 3 cDNA, was
subcloned into the pBluescript II SK(1) vector. A 40-bp deletion
was created within the cDNA insert by digestion of the plasmid
with BspEIyTth111I and religation. The resulting plasmid was
cut with SacII, and artificial run-off RNA was generated by using
the T7 MEGAscript kit (Ambion). To study expression of the
RASSF1A and VHL genes, predetermined amounts of these
RNAs were added to 1.5 mg of total RNA or 0.5 mg of poly(A)1
RNA.
Reverse transcription was conducted by using the RETRO-
script kit (Ambion). cDNA was used for PCR amplification
(95°C for 30 sec and 72°C for 40 sec, using from 20 to 35 cycles,
depending on the amount of PCR product). The primers used
were F2.1A-1D, AGC GCC CAA AGC CAG CGA AGC ACG
G and F2.1A-1R, CCC GCA ACA GTC CAG GCA GAC GAG
C. When higher sensitivity was required, a nested PCR was
performed by using the primers F2.1A-2D, TGA GCT CAT
TGA GCT GCG GGA GCT GGC A and F2.1A-2R, GGC AGC
GGT AGT GGC AGG TGA ACT TGC A. PCR products were
separated in a 4–20% TBE (90 mM Trisy64.6 mM boric acidy2.5
mM EDTA, pH 8.3) polyacrylamide gel (Invitrogen).
Mutation Screening. PCR amplification of exons 1a and 2ab was
performed by using genomic primers 1Fwup, CTC TAG CAC
AGT AAA GCT GGC; 2ARv, AGC CAC CTC TGC TCA TCT
GTG G, and nested primer 1Fw, CTC TCC TCA GCT CCT TCC
(for exon 1); plus intronic primers 4Fw, CTG GGG CTT CCC
TTC AAT CTC; 4Rv, AGC TCC AGC GAC CGC TTC; and
3ARv, CAA GCG CAC AAG AGT GGC CTC for exon 2. The
cycling conditions were 4 min at 94°C, 30 sec at 94°C, 30 sec at
60°C, and 1 min at 72°C, for 35 cycles, followed by 7 min at 72°C.
The PCR-amplified DNA was cloned and sequenced.
Reexpression of RASSF1A After 5-Aza-2*-deoxycytidine (5-Aza-CdR)
Treatment. RCC cells (786-0) were treated with 5 mM of 5-Aza-
CdR for 4 days, and the total RNA from these cells was analyzed
along with RNA from untreated 786-0 cells and normal kidney
RNA, purchased from Invitrogen. For each of these three
samples, 5 reverse transcription (RT) reactions were set up, each
containing different amounts of artificial RASSF1A RNA (1 ng,
100 pg, 10 pg, 1 pg, or 100 fg). Total cellular RNA (1.5 mg) was
used per RT reaction. PCR was performed as described, and the
products were run on 4–20% polyacrylamide gels (Invitrogen).
Cell-Growth Assays. RASSF1A cDNA was cloned into the
pcDNA3.1 (Invitrogen) expression vector and transfected into
KRCyY RCC cells by using lipofectamine. Geneticin-resistant
colonies were expanded and 5 3 104 cells were mixed with 1.5
ml of agar (0.3% in DMEM) and overlaid on 5 ml of 0.5% plating
agar in DMEM (in 60 3 15-mm Petri dishes). After 10 days, the
plates were stained with neutral red, and colonies with a
diameter of greater than 100 mm and less than 100 mm were
counted separately. To study growth on plastic Petri dishes,
wild-type and mutant RASSF1A, containing Cys65Arg and
Val211Ala amino acid changes were, cloned into a pETE
episomal tetracycline-regulated vector (J.L. and E.Z., unpub-
lished results). These constructs and the original pETE vector
were transfected into a KRCyY cell line constitutively producing
tTA (A.P. and E.Z., unpublished results). In the absence of
tetracycline or doxycycline (dox), RASSF1A genes were ex-
pressed, whereas in the presence of 500 ngyml of dox, no
expression occurred. G4180-resistant clones were selected and
wild-type RASSF1A clone 1, mutant RASSF1A clone 2, and
pETE clone 1 were used in further experiments. Growth of the
cells was monitored daily in the presence and absence of dox.
Cells from 3 parallel dishes were counted.
Results
RASSF1A Is Hypermethylated in Primary Clear RCC Tumors and in RCC
Cell Lines. A moderately GC-rich putative promoter of the
RASSF1A transcript was located immediately downstream from
the 39 end of the BLU gene (Fig. 4A, which is published as
supplemental data on the PNAS web site, www.pnas.org). Pro-
moter methylation was analyzed by COBRA or methylation-
specific PCR by using DNA samples from primary clear RCC
tumors and matching normal kidney DNA. Normal kidney DNA
was isolated from visually unaffected renal parenchyma, as
shown by staining with hematoxylin and eosin. Control normal
tissue was free of tumor cells, whereas contamination of tumor
by normal cells was less than 30%. RASSF1A–methylation-
specific PCR analysis was performed as described elsewhere
(20). For COBRA analysis of the putative RASSF1A promoter,
we used four BstUI CGCG-recognition sites (Fig. 4B, which is
published as supplemental data on the PNAS web site), which
remain preserved only after bisulfite treatment if both CG
dinucleotides (CpG) within the DNA recognition sequence are
methylated. The inability of BstUI to cut the PCR products
would indicate that the original genomic fragment is unmethyl-
ated. The same genomic fragment also contains MspI sites
(CCGG), which would be eliminated after bisulfite conversion in
both methylated and unmethylated DNA. Therefore, the MspI
digest was used to ensure that this conversion was complete.
We found complete or partial methylation in 39 of 43 tumor
samples (91%). In the remaining four tumors, no mutations or
single-nucleotide polymorphisms were found within exons 1a
and 2ab after sequencing. For 29 of these 43 samples (67%), the
normal kidney DNA was available from the same patient.
According to methylation-specific PCR, in 27 of these 29 tumor-
normal pairs (93%), tumor DNA was hypermethylated always,
compared with the matching normal DNA, which in some cases
also was methylated but to a lesser extent. Six of these tumor-
Dreijerink et al. PNAS u June 19, 2001 u vol. 98 u no. 13 u 7505
M
ED
IC
A
L
SC
IE
N
CE
S
normal bisulfite-treated DNA pairs were amplified by PCR,
subcloned, and sequenced (Fig. 5, which is published as supple-
mental data on the PNAS web site). In each pair, tumor DNA
was hypermethylated, compared with normal matching kidney
DNA. Contamination of tumor with normal kidney DNA in
these preparations cannot be excluded, thus the actual difference
in these pairs is likely to be even greater. As we could observe
partial methylation in normal control DNA (DNA from normal
tissue in close proximity to tumor tissue), these results indicate
that silencing the RASSF1A promoter might be an early event
in the carcinogenesis of some clear RCC. A partial or complete
methylation was observed for all 18 studied RCC lines (Fig. 1).
RASSF1A Hypo- and Hypermethylated Alleles Are Maintained Simul-
taneously in Somatic-Cell Hybrids. We studied RASSF1A transcrip-
tion and methylation in RCC somatic-cell hybrid clones that were
created earlier for VHL studies (22). Both parental lines
(UOK121 and UMRC6) contained multiple copies of chromo-
some 3 (5–6 copies; data not shown). We found that in UOK121
cells, the RASSF1A transcript was expressed, and at least some
of the copies of chromosome 3 carried a hypomethylated
RASSF1A promoter. In UMRC6 cells, the gene was silenced
and methylated. The presence of chromosome 3 from both
parental cell lines in somatic-cell hybrids was confirmed by using
an informative single-nucleotide polymorphism located within 39
untranslated region (UTR) of the VHL gene (24). Analysis of the
cell hybrids indicated that RASSF1A maintained normal expres-
sion in one of four clones comparable to that of the parental
UOK121 line. Sequencing of bisulfite-treated DNA from this
hybrid revealed the presence of both heavily methylated and
hypomethylated copies of the RASSF1A promoter (Fig. 6, which
is published as supplemental data on the PNAS web site). This
fact may point to various cis elements potentially important for
maintenance of a stable methylation pattern in this region. Both
hypo- and hypermethylated alleles also are maintained in the
duplicated chromosomes of the partially methylated cell lines
HN51, A498, CAKI 2, and TK164 (data not shown).
RASSF1C Promoter Is Not Methylated in RCC Cell Lines and Primary
Renal Tumors. The CpG islands that coincided with exon 1a of
RASSF1A and exon 2g of the RASSF1C transcription units (Fig.
4A, which is published as supplemental data on the PNAS web
site) have similar sizes and GC contents and are 4 kb apart.
However, we found, that in contrast to RASSF1A, this island
never was methylated in the same set of primary renal tumors.
Consequently, the RASSF1C transcript is always present in these
cells (data not shown). Interestingly, the RASSF1C has been
reported to be silenced in some ovarian tumor samples (25).
Transcriptional Silencing of RASSF1A Correlates with DNA Methyl-
ation. RASSF1A expression was analyzed in 18 RCC cell lines by
Northern blot analysis and quantitative RT-PCR. We found a
hypermethylated promoter and low (or absent) RASSF1A ex-
pression in nine lines (ACHN, HN4, HN51, CAKI 2, UMRC6,
786-0, RFX393, UOK108, and UOK127).
Seven cell lines had partial methylation of the promoter and
moderate to normal expression levels of the RASSF1A tran-
script (KH39, CAKI 1, TK164, KRCyY, UOK102, UOK121 and
UOK143). The remaining two cell lines, TK10 and A498,
expressed high levels of RASSF1A. For three RASSF1A-
expressing cell lines (TK10, KRCyY, and CAKI 1), sequencing
of the first two RASSF1A exons was performed. In TK10 and
KRCyY, a nonconservative change in the SH3 domain was found
(Lys-213Gln-21). In CAKI 1, another change in the SH3
domain was detected (Glu-63Asp-6).
In several cell lines (UMRC6, 786-0, KRCyY, RFX393,
UOK108, UOK121, UOK127, and UOK143), the interrelation
between RASSF1A expression and promoter methylation was
analyzed in detail. To determine the methylation status of each
CpG dinucleotide, COBRA PCR fragments were subcloned and
several clones from each cell line were sequenced (Fig. 1 A and
B). To estimate the level of RASSF1A expression in normal
kidney and tumor samples by quantitative RT-PCR, a predeter-
mined amount of artificial RASSF1A RNA carrying a 20-bp
deletion was added to the RNA samples before RT. After
RT-PCR, the artificial RNA with a 20-bp deletion yielded a
shorter PCR fragment. The amount of native and artificial
RASSF1A RNA in the sample was estimated by comparing the
intensities of the normal and control PCR bands (Fig. 1C).
According to the RT-PCR quantitation, RASSF1A mRNA is
expressed in normal kidney at the level of 0.01% of the total
mRNA level. The expression level in the cell lines carrying
methylated RASSF1A promoter, including UMRC6, 786-0,
RFX393, UOK108, and UOK127, was below 0.001%. In three
‘‘semimethylated’’ cell lines, expression varied between 0.001–
0.02% (Fig. 1C). In general, the extent of methylation of the
GC-rich genomic region at the 59 end correlated with RASSF1A
transcriptional repression.
Reexpression of RASSF1A in RCC Cells After 5-Aza-CdR Treatment. In
the 786-0 RCC cell line, RASSF1A transcription is silenced and
the putative promoter region is methylated heavily (Fig. 1).
RASSF1A transcription was reactivated after incubation of 786-0
cells for 3 days in the medium containing 5 mM of the DNA
methylation inhibitor 5-Aza-CdR (Fig. 2). RT-PCR quantitation
revealed a 50- to 100-fold increase in RASSF1A mRNA expres-
sion. Therefore, transcriptional repression is at least in part
mediated by DNA methylation.
Reexpression of RASSF1A in tTA-Engineered KRCyY Cells Suppresses
Growth on Plastic Surfaces. Cells were transfected with the epi-
somal pETE–RASSF1A constructs, selected and grown on
plastic Petri dishes in the presence and absence of dox. They were
monitored daily by counting cells from triplicate dishes (see
Materials and Methods). As shown (Fig. 3A), the wild-type allele
drastically suppressed cell growth in the absence of dox (83%
suppression on day 6 and 91% on day 12) compared with the
empty control vector, whereas the mutant gene was much less
effective (64% suppression on day 6 and 69% on day 12). In the
presence of dox, no difference in growth rate was detected
among these clones.
Reexpression of RASSF1A in KRCyY Cells Suppresses Anchorage-
Independent Growth. The expressing construct pcDNA3.1-
RASSF1A was transfected into KRCyY cells. G418-resistant
RASSF1A-expressing clones were expanded. The numbers of
small (size 20–100 mm) and large (size 100 mm and more)
colonies were decreased for the RASSF1A-expressing cells after
10 days of growth in soft agar. In general, the number of colonies
formed by RASSF1A-transfected cells was only 5% of those
from the control cells (Fig. 3B). After 15 days, the original
KRCyY cells comprised a continuous layer of cells. In contrast,
RASSF1A-transfected clones expanded at a much lower rate,
forming spheroid bodies (Fig. 7, which is published as supple-
mental data on the PNAS web site, www.pnas.org).
Discussion
Allelic losses on 3p12-p14, 3p21-p22, and 3p25-p26 are the most
frequent events in the genesis of nonpapillary RCC. The FHIT
gene, located within the first region at 3p14.2, was down-
regulated in more than 50% of clear RCC tumors examined (15).
The VHL tumor-suppressor gene identified at 3p25 was inacti-
vated in 100% of VHL families and in a large percentage of
sporadic clear RCC (8–10). To date, no clear RCC candidate
TSGs have been found in the 3p21-p22 region. This region is now
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Fig. 1. Correlation of promoter methylation and RASSF1A expression in clear RCC tumor cell lines. (A) COBRA. For COBRA analysis, PCR fragments were
amplified by using bisulfite-treated genomic DNA and nested primers shown in Fig. 4B, which is published as supplemental data on the PNAS web site. PCR
fragments were digested with BstUI or MspI. BstUI cuts revealed the presence of methylated CpGs in the original DNA. The absence of MspI cuts confirmed proper
conversion of unmethylated cytidines. (B) Sequencing of bisulfite-treated amplified DNA. For detailed methylation analysis of the COBRA PCR products, the
fragments were subcloned, and several plasmid clones were sequenced for each cell line. Yellow and green squares represent unmethylated and methylated
CpGs, respectively. Thirty-two CpGs located between nested COBRA primers (Fig. 4B, which is published as supplemental data on the PNAS web site) are
numbered, starting from NT 17782. CpGs located within BstUI-cutting sites are highlighted in gray. The positions of the 59 end of RASSF1A cDNA and the RASSF1A
initiation codon are marked. (C) RT-PCR quantitation of the RASSF1A transcript. The upper band in each gel shows control RT-PCR using 1.5 mg of normal kidney
mRNA per lane. The lower gel shows RT-PCR amplification using mRNA from the eight RCC cell lines (same conditions). The lower band in each gel corresponds
to the different amount (1 ng, 100pg, 10 pg, or 1 pg) of artificial truncated RASSF1A RNA added to the RT reaction. Upper bands are produced from the
endogenous RASSF1A mRNA. The percentage of endogenous RASSF1A mRNA was calculated for each cell line and shown on the left.
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subdivided into the centromeric 3p21.3 and the telomeric 3p21.3-
p22 subparts (5).
Here we present, to our knowledge, the first evidence to
support the potential role of the candidate lung and breast
cancer TSG, RASSF1A, in the development of clear RCC
tumors. Surprisingly, this 3p21.3 gene (from centromeric subre-
gion 3p21.3) was involved in both types of clear RCC, i.e., with
and without VHL inactivation.
The RASSF1A gene was hypermethylated in 91% of primary
clear RCC tumors (39 of 43 tumors). In 27 of 29 available
tumor-normal pairs, the RASSF1A promoter was hypermethyl-
ated in tumor DNA. In normal matching DNA from tumor-
surrounding tissues, the RASSF1A promoter was methylated also
albeit to a much lesser extent, suggesting that silencing of it might
be a causative early event in the carcinogenesis of some clear
RCC preceding or after LOH.
In RCC cell lines, hypermethylation of the RASSF1A pro-
moter region correlated with transcriptional down-regulation of
the RASSF1A mRNA. Interestingly, the nearby RASSF1C
promoter was found unmethylated in all renal tumor samples
and cell lines. Both RASSF1A and RASSF1C predicted proteins
show high homology (55% identity) to the mouse RAS effector
protein Nore1 and to the rat orthologous protein Maxp1 (19).
Nore1 interaction with Ras is GTP-dependent and follows
receptor activation. However, RASSF1A and RASSF1C pro-
teins have different NH2 termini. The RASSF1C N-terminal
sequence has no similarity to any known proteins, whereas the
N-terminal part of RASSF1A contains SH3 (residues 1–51) and
diacylglycerolyphorbolester-binding (DAG) domain (residues
52–101) domains in addition to the common RAS-association
domain (19, 20). All of these domains may involve the RASSF1A
protein in signal-transduction pathways and define its important
tumor-suppressor properties. Finding amino acid changes (Lys-
213Gln-21 and Glu-63Asp-6) in three RASSF1A-expressing
clear RCC cell lines (this work) and multiple changes in the
SH3-, DAG-, and RAS-association domains in lung cancer cells
(19–21) strengthens this possibility.
RASSF1A suppressed the growth of KRCyY cells in Petri
dishes and anchorage-independent growth in soft agar. The
specificity of these activities was supported by the absence of
suppression in the presence of dox when the transgenes were not
Fig. 2. Reexpression of RASSF1A gene in 786-0 cells. The cells were grown in
5 mM 5-Aza-CdR for 4 days. Total RNA (1.5 mg ) was used per RT reaction. The
amount of artificial truncated RASSF1A RNA added per each RT reaction is
indicated on the top.
Fig. 3. Suppression of KRCyY cell growth by RASSF1A reexpression. (A) Growth suppression of RASSF1A-transfected cells on plates. (B) Colony count of
RASSF1A-transfected and control cells in soft agar.
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expressed. Moreover, the mutant RASSF1A with mutations in
diacylglycerolyphorbolester-binding- and RAS-associated
domains possessed significantly reduced growth-suppressing
activity.
Suppression of RASSF1A transcription did not correlate with
the status of the VHL gene. In RFX393, UOK108, UOK121,
UOK127, and UOK143 cell lines, the VHL gene was silenced by
hypermethylation (10, 22), but the RASSF1A was hypermethy-
lated only in RFX393, UOK108, and UOK127. RASSF1A
wild-type mRNA was expressed in the remaining ‘‘VHL-
methylated’’ lines UOK121 and UOK143. UMRC6 and 786-0
carried mutations of the VHL gene (8, 9) and methylated
(silenced) RASSF1A alleles. Finally, KRCyY cells had a nor-
mally expressed VHL gene and expressed RASSF1A that en-
codes a nonconservative amino acid change. Simultaneous in-
activation of both genes in one cell line would imply that VHL
and RASSF1A proteins participate in different tumorigenic
pathways. Indeed, multiple 3p LOH (at 3p25-p26 and 3p21-p22)
are common in nonpapillary RCC (4, 5, 17) and can occur at
different stages of tumor development in the same tumor.
Inactivation of RASSF1A in clear RCCs that possessed a nor-
mally expressed VHL implies an important role of the gene in the
origin of this type of clear RCC. On the other hand, its
inactivation in VHL-caused tumors suggests a role in tumor
development. Thus, the RASSF1A gene could play a dual role in
carcinogenesis, being causally involved in the origin of some clear
RCCs and driving progression of some VHL-caused clear RCCs.
Coexistence of hypo- and hypermethylated gene copies in the
same cell or partial methylation of the same copy can cause only
partial down-regulation of the RASSF1A transcript in a large
proportion of RCC cell lines and primary tumors. However, our
growth-suppression experiments indicate that even a partial
RASSF1A repression, sometimes in conjunction with amino acid
changes, may provide important selective advantages for the
growth of affected cells.
It seems that clear RCC is characterized by genetic hetero-
geneity with different pathologically indistinguishable forms
caused by separate TSGs. They were described originally as
conforming to the two-hit paradigm (26, 27). However, recent
data suggest that multiple hits are required in clear RCC
development (28). These hits may include different tumor-
suppressor genes located on chromosomes 3p25-p26, 3p21-p22,
(subregions, centromeric 3p21.3 and 3p21.3-p22) and 3p12-p14.
Numerous studies have shown that 3p21-p22 LOH is the most
frequent loss in sporadic nonpapillary RCC, although 3p25-p26
and 3p12-p14 losses usually occur earlier in some tumor devel-
opment. When multiple LOH are present, tumors with LOH on
3p21-p22 also carry LOH on 3p14 or 3p25 (5, 16, 17), suggesting
that LOH on 3p21-p22 is an important event in RCC progres-
sion. However, another study of multiple tumors from a single
patient established that early 3p allelic losses (adenoma but not
carcinoma-related) occurred predominantly in the 3p25 or the
3p12-p14 regions, but not in 3p21–3p22 (29). On the other side,
the non-VHL hereditary clear RCC locus was excluded by
linkage analysis from chromosome 3p, implying that losses of 3p
genes are not involved in the origin of this particular hereditary
form of clear RCC (12).
The present data suggest that RASSF1A is the candidate renal
3p21.3 TSG. More studies are necessary to elucidate the role of
RASSF1A in other multiple types of human cancer.
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